DK1380303T3 - Kombinationsterapi til behandling af hepatitis B-virus - Google Patents

Kombinationsterapi til behandling af hepatitis B-virus

Info

Publication number
DK1380303T3
DK1380303T3 DK03077542T DK03077542T DK1380303T3 DK 1380303 T3 DK1380303 T3 DK 1380303T3 DK 03077542 T DK03077542 T DK 03077542T DK 03077542 T DK03077542 T DK 03077542T DK 1380303 T3 DK1380303 T3 DK 1380303T3
Authority
DK
Denmark
Prior art keywords
virus
combination
alternation
administering
directed
Prior art date
Application number
DK03077542T
Other languages
English (en)
Inventor
George R Painter
Franck Rousseau
Phillip A Furman
David Barry
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK1380303T3 publication Critical patent/DK1380303T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03077542T 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus DK1380303T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10666498P 1998-11-02 1998-11-02
PCT/US1999/025673 WO2000025797A1 (en) 1998-11-02 1999-11-02 Combination therapy to treat hepatitis b virus

Publications (1)

Publication Number Publication Date
DK1380303T3 true DK1380303T3 (da) 2008-12-01

Family

ID=22312611

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03077542T DK1380303T3 (da) 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus
DK03077543.1T DK1382343T3 (da) 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03077543.1T DK1382343T3 (da) 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus

Country Status (16)

Country Link
US (3) US6528515B1 (da)
EP (3) EP1380303B1 (da)
JP (2) JP2002528508A (da)
KR (1) KR100632520B1 (da)
CN (3) CN1173705C (da)
AT (3) ATE457734T1 (da)
AU (1) AU1810600A (da)
CY (2) CY1108635T1 (da)
DE (3) DE69923338T2 (da)
DK (2) DK1380303T3 (da)
ES (3) ES2237189T3 (da)
HK (1) HK1062146A1 (da)
ID (1) ID29471A (da)
IL (3) IL142910A0 (da)
PT (2) PT1382343E (da)
WO (1) WO2000025797A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1382343E (pt) * 1998-11-02 2010-03-10 Gilead Sciences Inc Terapia de combinação para tratamento do vírus da hepatite b
ES2345099T3 (es) * 2002-06-19 2010-09-15 Fideline Feromonas tranquilizantes aviarias para disminuir el estres, la ansiedad y la agresividad.
CA2492554A1 (en) * 2002-07-15 2004-01-22 Gilead Sciences, Inc. Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WO2004064846A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2011145808A2 (ko) * 2010-05-18 2011-11-24 부광약품 주식회사 클레부딘 및 아데포비어 디피복실을 함유하는 만성 b형 간염 치료용 조성물
KR20100127180A (ko) * 2009-05-25 2010-12-03 부광약품 주식회사 클레부딘 및 아데포비어 디피복실을 함유하는 만성 b형 간염 치료용 조성물
CA2819548C (en) 2010-12-10 2019-04-09 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
EP3294745B1 (en) * 2015-05-08 2020-01-01 H. Hoffnabb-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
CN105943547B (zh) * 2016-05-23 2018-01-19 北京慧宝源生物技术股份有限公司 抗hbv的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
JPH05507279A (ja) 1990-05-29 1993-10-21 ネクススター・ファーマシューティカルズ・インコーポレイテッド グリセロールジ―およびトリホスフェート誘導体の合成
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US5674869A (en) * 1990-07-07 1997-10-07 Beecham Group Plc Pharmaceutical treatment
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
EP0594677A4 (en) 1991-07-12 1997-09-17 Vical Inc Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
AU701574B2 (en) 1993-05-12 1999-02-04 Karl Y. Hostetler Acyclovir derivatives for topical use
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
WO1998023285A1 (en) * 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
CA2287370C (en) * 1997-03-19 2010-02-09 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
PT1382343E (pt) * 1998-11-02 2010-03-10 Gilead Sciences Inc Terapia de combinação para tratamento do vírus da hepatite b

Also Published As

Publication number Publication date
EP1124562B1 (en) 2005-01-19
IL193148A0 (en) 2009-02-11
ID29471A (id) 2001-08-30
ATE287268T1 (de) 2005-02-15
CN1329497A (zh) 2002-01-02
EP1380303B1 (en) 2008-09-17
US20030158150A1 (en) 2003-08-21
ATE457734T1 (de) 2010-03-15
EP1124562A1 (en) 2001-08-22
CN1666742A (zh) 2005-09-14
JP2002528508A (ja) 2002-09-03
CY1110629T1 (el) 2015-04-29
CN1891221A (zh) 2007-01-10
US6528515B1 (en) 2003-03-04
DE69923338D1 (de) 2005-02-24
US7572800B2 (en) 2009-08-11
PT1380303E (pt) 2008-11-03
DE69923338T2 (de) 2006-04-06
CY1108635T1 (el) 2014-04-09
IL193148A (en) 2011-09-27
KR20010082282A (ko) 2001-08-29
US20090247487A1 (en) 2009-10-01
ES2314157T3 (es) 2009-03-16
IL142910A (en) 2009-06-15
ES2338642T3 (es) 2010-05-11
HK1062146A1 (en) 2004-10-21
CN1173705C (zh) 2004-11-03
EP1380303A1 (en) 2004-01-14
ES2237189T3 (es) 2005-07-16
DK1382343T3 (da) 2010-04-26
KR100632520B1 (ko) 2006-10-09
WO2000025797A1 (en) 2000-05-11
JP2011079840A (ja) 2011-04-21
AU1810600A (en) 2000-05-22
PT1382343E (pt) 2010-03-10
IL142910A0 (en) 2002-04-21
ATE408410T1 (de) 2008-10-15
DE69939604D1 (de) 2008-10-30
EP1382343B1 (en) 2010-02-17
DE69942042D1 (de) 2010-04-01
EP1382343A1 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
CY1110629T1 (el) Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
YU96192A (sh) Trombin i postupak za njegovu proizvodnju
ATE329598T1 (de) 1,3-oxathiolane zur behandlung von hepatitis
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
ATE346651T1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
ATE146968T1 (de) Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
BR9808221A (pt) Método de tratamento de tumor.
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
ATE150317T1 (de) Synergische mischung zur behandlung von herpes
PT948967E (pt) Tratamento de doencas virais em suicos
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
FI945035A (fi) Pintasterilisointi laserkäsittelyn avulla
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.